NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Wednesday a U.S. appeals court upheld a lower court’s denial of the company’s right to sell a generic version of Procter & Gamble’s osteoporosis drug Actonel. The U.S. Court of Appeals for the Federal Circuit affirmed a Feb. 29, 2008 District Court decision to uphold P&G’s patent on the drug. Israel-based Teva said it will not sell a generic version of the drug until the patent expires in 2014. Actonel was approved in 2000 by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. Osteoporosis is a condition that causes weak bones that are more likely to fracture over time.
Related Articles Read More >
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
